SOURCE: Given Imaging

Given Imaging

September 08, 2011 07:00 ET

Creator of PillCam®, Given Imaging to Ring The NASDAQ Stock Market Closing Bell on September 12, 2011

Company Celebrates 10th Anniversary of Initial Public Offering

NEW YORK, NY--(Marketwire - Sep 8, 2011) - Given Imaging (NASDAQ: GIVN), a world leader in GI medical devices and pioneer of capsule endoscopy, today announced it will ring The NASDAQ Stock Market Closing Bell to commemorate its 10th anniversary as a publicly traded company on September 12, 2011. In recognition of this significant milestone, members of the Company's senior leadership team have been invited to preside over the official close of trading at The NASDAQ Stock Market that day from 3:45 to 4:00 pm ET.

"It is a great honor to lead the closing bell ceremony as we celebrate our 10th anniversary as a public company listed on The NASDAQ Stock Market," said Homi Shamir, president and chief executive officer of Given Imaging Ltd. "Over the past decade Given Imaging has built a strong track record of financial performance reflecting our leadership in the field of GI diagnostics that help to improve patient lives. Through the commitment of our more than 750 employees around the world to develop innovative products that advance and accelerate the detection of GI diseases, Given Imaging has changed the field of gastroenterology. More than 1.5 million patients suffering from gastrointestinal disorders have ingested our PillCam Capsules and we continue to expand our portfolio of products to evaluate the full range of GI conditions including PillCam COLON 2 which holds enormous potential for helping to increase compliance with colorectal screening guidelines. Looking ahead, we are committed to investing in and developing new products to improve GI health such as magnetically controlled PillCam capsules as well as PillCam capsules that can deliver therapeutics."

A live webcast of the closing bell ceremony will be available on the NASDAQ website ( beginning at 3:45 pm ET on September 12th.

"Having witnessed the evolution of PillCam capsule endoscopy from an investigative device to gold standard diagnostic test, I am proud to have worked closely with Given Imaging to expand our understanding of the potential of this valuable technology," said Blair Lewis, MD, Clinical Professor of Medicine, Mount Sinai Medical Center, New York... "PillCam SB has enhanced the way physicians diagnose disorders of the small bowel, changed clinical management decisions, and improved patients' lives."

The Company's flagship product, PillCam SB, was recently cleared for expanded indications, including the detection and monitoring of lesions indicating Crohn's disease. In June, Given Imaging announced the initiation of an 800 patient, multi-center, pivotal PillCam® COLON 2 study, which will support the Company's planned 510(k) submission to the U.S. Food and Drug Administration (FDA). Earlier this year, the entire Given Imaging product line was featured in more than 150 podium and poster presentations during Digestive Disease Week including data on ManoScan High Resolution Manometry, the Bravo® pH Monitoring System and Digirapper® pH-Z.

*Dr. Blair Lewis is a paid consultant of Given Imaging.

About Given Imaging Ltd.
Since pioneering the field of capsule endoscopy in 2001, Given Imaging has become a world leader in GI medical devices, offering health care providers a range of innovative options for visualizing, diagnosing and monitoring the digestive system. The company offers a broad product portfolio including PillCam® video capsules for the small bowel, esophagus and colon [PillCam® COLON not approved for use in the United States.], industry-leading ManoScan high-resolution manometry and Bravo® wireless and Digitrapper® pH and impedance products. Given Imaging is committed to delivering breakthrough innovations to the GI community and supporting its ongoing clinical needs. Given Imaging's headquarters are located in Yoqneam, Israel, with operating subsidiaries in the United States, Germany, France, Japan, Australia, Vietnam and Hong Kong. For more information, please visit

The NASDAQ OMX Group, Inc. is the world's largest exchange company. It delivers trading, exchange technology and public company services across six continents, with more than 3,500 listed companies. NASDAQ OMX offers multiple capital raising solutions to companies around the globe, including its U.S. listings market, NASDAQ OMX Nordic, NASDAQ OMX Baltic, NASDAQ OMX first North, and the U.S. 144A sector. The company offers trading across multiple asset classes including equities, derivatives, debt, commodities, structured products and exchange-traded funds. NASDAQ OMX technology supports the operations of over 70 exchanges, clearing organizations and central securities depositories in more than 50 countries. NASDAQ OMX Nordic and NASDAQ OMX Baltic are not legal entities but describe the common offering from NASDAQ OMX exchanges in Helsinki, Copenhagen, Stockholm, Iceland, Tallinn, Riga, and Vilnius. For more information about NASDAQ OMX, visit *Please follow NASDAQ OMX on Facebook ( and Twitter (

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, projections about our business and our future revenues, expenses and profitability. Forward-looking statements may be, but are not necessarily, identified by the use of forward-looking terminology such as "may," "anticipates," "estimates," "expects," "intends," "plans," "believes," and words and terms of similar substance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual events, results, performance, circumstances or achievements of the Company to be materially different from any future events, results, performance, circumstances or achievements expressed or implied by such forward-looking statements. Factors that could cause actual events, results, performance, circumstances or achievements to differ from such forward-looking statements include, but are not limited to, the following: (1) our ability to develop and bring to market new products, (2) our ability to successfully complete any necessary or required clinical studies with our products, (3) our ability to receive regulatory clearance or approval to market our products or changes in regulatory environment, (4) our success in implementing our sales, marketing and manufacturing plans, (5) the level of adoption of our products by medical practitioners, (6) the emergence of other products that may make our products obsolete, (7) lack of an appropriate bowel preparation materials to be used with our PillCam COLON capsule, (8) protection and validity of patents and other intellectual property rights, (9) the impact of currency exchange rates, (10) the effect of competition by other companies, (11) the outcome of significant litigation, (12) our ability to obtain reimbursement for our product from government and commercial payors, (13) quarterly variations in operating results, (14) the possibility of armed conflict or civil or military unrest in Israel, (15) the impact of global economic conditions, (16) our ability to successfully integrate acquired businesses, (17) changes and reforms in applicable healthcare laws and regulations, (18) adverse events or product quality issues that could require us to recall products and impact our sales, and (19) other risks and factors disclosed in our filings with the U.S. Securities and Exchange Commission, including, but not limited to, risks and factors identified under such headings as "Risk Factors," "Cautionary Language Regarding Forward-Looking Statements" and "Operating Results and Financial Review and Prospects" in the Company's Annual Report on Form 20-F for the year ended December 31, 2010. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except for the Company's ongoing obligations to disclose material information under the applicable securities laws, it undertakes no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.

Contact Information